Brainstorm announces presentation of nurown® exosome preclinical data at isct 2022 san francisco meeting

Nurown-derived exosomes showed more potent anti-inflammatory effects in vitro compared to naÏve mesenchymal stem cell-derived exosomes new york , may 4, 2022 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "msc-ntf derived small extracellular vesicles display superior macrophage immunomodulation compared with vesicles derived from naÏve mscs," at the international society of  cell & gene therapy isct 2022 meeting, being held from may 4-7, 2022 in san francisco, ca. the poster will be presented by dr. kim thacker, senior vice president, medical affairs and clinical innovation, brainstorm cell therapeutics.
BCLI Ratings Summary
BCLI Quant Ranking